The characteristics of the modern structure of opioids as causes of acute poisoning (overdose): in focus the synthetic opioids | Український Медичний Часопис

Kurdil N.V.,Ivashchenko O.V.

Головна
Публікації
The characteristics of the modern structure of opioids as causes of acute poisoning (overdose): in focus the synthetic opioids

The characteristics of the modern structure of opioids as causes of acute poisoning (overdose): in focus the synthetic opioids

16 квітня 2021

798

Anesthesiology and Intensive care

Ключові слова :

Спеціальності :

Anesthesiology and Intensive care

Резюме

In recent years, new synthetic drugs have spread rapidly in many parts of the world, and the risks of fatal overdoses are extremely high.

The aim is to determine the features of the modern structure of narcotic drugs of the opioid group, which most often cause poisoning (overdose), and their toxic characteristics.

Material and methods. A retrospective analysis of the data of the Toxicological Center of the Municipal Non-Commercial Enterprise «Kyiv City Clinical Ambulance Hospital» on the results of monitoring the structure of narcotic substances that caused acute poisoning (overdose) among the adult population of Kyiv in 1990–2020.

Results. Over the past 10 years, the number of positive tests performed during the year for methadone has increased 150, morphine and tramadol — 100, heroin — 6 times; instead, the number of tests for natural opium («shirka») decreased by 7 times. Since 2017, cases of drug poisoning, which include various fentanyl analogues (acetylfentanyl, butyrylfentanyl, furanylfentanyl, etc.), have been regularly registered. It has been found that small amounts of new synthetic opioids are added to designer drugs (heroin, «ecstasy»), significantly increasing the risk of overdose and death on the street. The high toxicity of new synthetic opioids necessitates the improvement of existing protocols for the provision of medical care for opioid poisoning in the use of antidotes, tracheal intubation and pulmonary ventilation in the prehospital stage.

Conclusion. Synthetic opioids are a new trend in the field of designer drugs, and the growing number of fatal poisonings associated with their use is creating new challenges for emergency physicians and toxicologists.

References:

1. EMCDDA (2020) Looking back on 25 years of annual reporting on the drugs problem in Europe (https://www.emcdda.europa.eu/publications/brochures/25-years-annual-reporting_en).
2. EMCDDA (2020) European Drug Report 2020: Trends and Developments (https://www.hareact.eu/ru/node/6080).
3. EMCDDA (2015) Drug profiles (http://www.emcdda.europa.eu/drug-profiles).
4. Wilson N., Kariisa M., Seth P. et al. (2020) Drug and Opioid-Involved Overdose Deaths — United States, 2017–2018. MMWR Morb. Mortal. Wkly Rep., 69(11): 290–297. doi:10.15585/mmwr.mm6911a4.
5. Tori M.E., Larochelle M.R., Naimi T.S. (2020) Alcohol or Benzodiazepine Co-involvement With Opioid Overdose Deaths in the United States, 1999–2017. JAMA Network Open, 3(4): e202361. doi:10.1001/jamanetworkopen.2020.2361.
6. Beardsley P.M., Zhang Y. (2018) Synthetic Opioids. Handb. Exp. Pharmacol., 252: 353–381.doi: 10.1007/164_2018_149.
7. Clark D.J., Schumacher M.A. (2017) America’s Opioid Epidemic: Supply and Demand Considerations. Anesth. Analg., 125(5): 1667–1674. doi: 10.1213/ANE.0000000000002388.
8. Prekupec M.P, Mansky P.A, Baumann M.H. (2017) Misuse of Novel Synthetic Opioids: A Deadly New Trend. J. Addict. Med., 11(4): 256–265. doi: 10.1097/ADM.0000000000000324.
9. Barbosa L.M., Santos J.M., de Morais D.R. et al. (2019) Fast UHPLC-MS/MS method for analysis of furanylfentanyl in different seized blotter papers. Drug Test Anal., 11(1): 178–183. doi: 10.1002/dta.2472.
10. Concheiro M., Chesser R., Pardi J. et al. (2018) Postmortem Toxicology of New Synthetic Opioids. Front. Pharmacol., 9: 1210. doi: 10.3389/fphar.2018.01210.
11. Pasternak G.W., Pan Y.X. (2013) Mu opioids and their receptors: evolution of a concept. Pharmacol Rev. , 65(4): 1257–317. doi: 10.1124/pr.112.007138.
12. Armenian P., Vo K.T., Barr-Walker J. et al. (2018) Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review. Neuropharmacology, 134(Pt A): 121–132. doi: 10.1016/j.neuropharm.2017.10.016.
13. Fornili K.S. (2019) International Control Efforts to Curb the Global Production and Trafficking of Fentanyl and Other Synthetic Opioids. J. Addict. Nurs., 30(1): 71–76. doi: 10.1097/JAN.0000000000000269.
14. Pichini S., Solimini R., Berretta P. et al. (2018) Acute Intoxications and Fatalities From Illicit Fentanyl and Analogues: An Update. Ther. Drug Monit., 40(1): 38–51. doi: 10.1097/FTD.0000000000000465.
15. Acuna V.S., Abels E.M., Alhelwani A. et al. (2020) Treating Non-fentanyl-derived Synthetic Opioid. Overdose with a Traditional Opioid Reversal Agent. Cureus, 12(3): e7241. doi: 10.7759/cureus.7241.
16. Kim H.K., Nelson L.S. (2015) Reducing the harm of opioid overdose with the safe use of naloxone: a pharmacologic review. Expert. Opin. Drug Saf., 14: 1137–1146. doi: 10.1517/14740338.2015.1037274.
17. Traynor K. (2016) Experts weigh minimum naloxone dose as opioid crisis evolves. Am. J. Health Syst. Pharm., 73: 1892–1894. doi:10.2146/news160067.
18. Wilde M., Pichini S., Pacifici R.et al. (2019) Metabolic Pathways and Potencies of New Fentanyl Analogs. Front. Pharmacol., 10: 238.doi: 10.3389/fphar.2019.00238.
19. Rogers J.S., Rehrer S.J., Hoot N.R. (2016) Acetylfentanyl: an emerging drug of abuse. J. Emerg. Med., 50: 433–436. doi: 10.1016/j.jemermed.2015.10.014.
20. Poklis J., Poklis A., Wolf C. et al. (2016) Two fatal intoxications involving butyryl fentanyl. J. Anal. Toxicol., 40: 703–708. doi:10.1093/jat/bkw048.
21. Hendrickson R.G., Akpunonu P., Hughes A.R. et al. (2019) Highly potent fentanyl analogs: apnea from exposure to small quantities of ss-hydroxyfentanyl and furanylfentanyl. Clin. Toxicol. (Phila), 57(9): 813–815. doi: 10.1080/15563650.2018.1558233.
22. Guerrieri D., Rapp E., Roman M. et al. (2017) Postmortem and Toxicological Findings in a Series of Furanylfentanyl-Related Deaths. J. Anal. Toxicol., 41(3): 242–249. doi: 10.1093/jat/bkw129.
23. Rambaran K.A., Amin Z.M., Fleming S.W. et al. (2018) AH-7921: A review of previously published reports. Proc. (Bayl. Univ. Med. Cent.), 31(3): 303–306. doi: 10.1080/08998280.2018.1465320.
24. Katselou M., Papoutsis I., Nikolaou P et al. (2015) AH-7921: the list of new psychoactive opioids is expanded. Forensic Toxicol., 33(2): 195–201. doi: 10.1007/s11419-015-0271-z.
25. Armenian P., Olson A., Anaya A. et al. (2017) Fentanyl and a novel synthetic opioid U47700 masquerading as street «Norco» in Central California: a case report. Ann. Emerg. Med., 69: 87–90. doi: 10.1016/j.annemergmed.2016.06.014.
26. Ruan X., Chiravuri S., Kaye A.D. (2016) Comparing fatal cases involving U-47700. Forensic Sci. Med. Pathol., 12: 369–371. https://link.springer.com/article/10.1007/s12024-016-9795-8.
27. Elliott S.P., Brandt S.D., Smith C. (2016) The first reported fatality associated with the synthetic opioid 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47700) and implications for forensic analysis. Drug Test. Anal., 8: 875–879. doi: 10.1002/dta.1984.
28. Schneir A., Metushi I.G., Sloane C. et al. (2017) Near death from a novel synthetic opioid labeled U-47700: emergence of a new opioid class. Clin. Toxicol. (Phila), 55: 51–54. doi: 10.1080/15563650.2016.1209764.
29. Siddiqi S., Verney C., Dargan P. et al. (2015) Understanding the availability, prevalence of use, desired effects, acute toxicity and dependence potential of the novel opioid MT-45. Clin. Toxicol. (Phila), 53: 54–59. doi:10.3109/15563650.2014.983239.
30. Helander A., Backberg M., Beck O. (2014) MT-45, a new psychoactive substance associated with hearing loss and unconsciousness. Clin. Toxicol. (Phila), 52: 901–904. doi:10.3109/15563650.2014.943908.
31. Green T.C., Gilbert M. (2016) Counterfeit medications and fentanyl. JAMA Intern. Med., 176: 1555–1557. doi:10.1001/jamainternmed.2016.4310.
32. Leen J.L.S., Juurlink D.N. (2019) Carfentanil: a narrative review of its pharmacology and public health concerns. Can. J. Anaesth., 66(4): 414–421. doi: 10.1007/s12630-019-01294-y.
33. Huang X.P., Che T., Mangano T.J. et al. (2017) Fentanyl-related designer drugs W-18 and W-15 lack appreciable opioid activity in vitro and in vivo. JCI Insight, 2(22): e97222. doi: 10.1172/jci.insight.97222.
34. Alzghari S.K., Amin Z.M., Chau S. et al. (2017) On the Horizon: The Synthetic Opioid U-49900. Cureus, 9(9): e1679. doi: 10.7759/cureus.1679.
35. Helander A., Bäckberg M., Hultén P. et al. (2014) Detection of new psychoactive substance use among emergency room patients: Results from the Swedish STRIDA project. Forensic. Sci. Internat., 243: 23–29. doi:10.1016/j.forsciint.2014.02.022.
36. Zuckerman M., Weisberg S.N., Boyer E.W. (2014) Pitfalls of intranasal naloxone. Prehosp. Emerg. Care, 18: 550–554. doi:10.3109/10903127.2014.896961.
37. Kim H.K., Nelson L.S. (2015) Reducing the harm of opioid overdose with the safe use of naloxone: a pharmacologic review. Expert. Opin. Drug Saf., 14(7): 1137–46. doi: 10.1517/14740338.2015.1037274.
38. Schumann H., Erickson T., Thompson T.M. et al. (2008) Fentanyl epidemic in Chicago, Illinois and surrounding Cook County Clin Toxicol (Phila), 6(6): 501–506. doi: 10.1080/15563650701877374.
39. Abdulrahim D., Bowden-Jones O.; NEPTUNE group (2018) The misuse of synthetic opioids: harms and clinical management of fentanyl, fentanyl analogues and other novel synthetic opioids. Information for clinicians (https://www.emcdda.europa.eu/best-practice/evidence-summaries/naloxone-revert-synthetic-opioids-overdose_en).
40. Rudd R.A., Seth P., David F. et al. (2016) Increases in drug and opioid-involved overdose deaths — United States, 2010–2015. MMWR Morb. Mortal. Wkly Rep., 65: 1445–1452. doi: 10.15585/mmwr.mm655051e1.
41. Peterson A.B., Gladden R.M., Delcher C. et al. (2016) Increases in Fentanyl-Related Overdose Deaths — Florida and Ohio, 2013–2015. MMWR Morb. Mortal. Wkly Rep., 65: 844–849. doi: http://dx.doi.org/10.15585/mmwr.mm6536a9.
42. United Nations Office on Drugs and Crime (2017) Global Synthetic Drugs Assessment (http://www.unodc.org/documents/scientific/Global_Drugs_Assessment_2017.pdf).
43. Drug Enforcement Administration (2018) Schedules of Controlled Substances: Temporary Placement of Fentanyl-Related Substances in Schedule I (https://www.federalregister.gov/documents/2018/02/06/2018-02319/schedules-of-controlled-substances-temporary-placement-of-fentanyl-related-substances-in-schedule-i).
44. Armenian P., Vo K.T., Barr-Walker J.et al. (2018) Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review. Neuropharmacology, 134: 121–132. doi: 10.1016/j.neuropharm.2017.10.016.